Please wait...

Maximize the utility of
imaging biomarkers
to the benefit of
patients with arthritis.
Learn more about the project  

AutoPiX is a major international project focused on improving healthcare for people with rheumatic and musculoskeletal diseases (RMDs).

The AutoPiX project brings together pharmaceutical and medical technology partners with leading academic institutions to enhance the use of imaging biomarkers for patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA), collectively known as systemic arthritides.

It aims to develop advanced imaging tools and artificial intelligence (AI) models to better diagnose, monitor, and treat these conditions. These tools will make use of imaging biomarkers—like X-rays, ultrasounds, and MRIs—to provide more precise and personalised care.

AutoPiX is a major international project focused on improving healthcare for people with rheumatic and musculoskeletal diseases (RMDs).

The AutoPiX project brings together pharmaceutical and medical technology partners with leading academic institutions to enhance the use of imaging biomarkers for patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA), collectively known as systemic arthritides.

It aims to develop advanced imaging tools and artificial intelligence (AI) models to better diagnose, monitor, and treat these conditions. These tools will make use of imaging biomarkers—like X-rays, ultrasounds, and MRIs—to provide more precise and personalised care.

Learn more about the project  
Partners / J&J – Johnson & Johnson

J&J – Johnson & Johnson

At Johnson & Johnson, they believe health is everything. Their strength in healthcare innovation empowers them to build a world where complex diseases are prevented, treated, and cured, treatments are smarter and less invasive, and solutions are personal. Through their expertise in Innovative Medicine and MedTech, they are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver tomorrow's breakthroughs and profoundly impact health for humanity.

More here: https://www.jnj.com/

What is the role of J&J in Autopix

J&J is the project leader and co-lead WP1 and WP4 alongside Medical University of Vienna. If patients have consented, we are contributing anonymized images from our historical trials. These images support building and testing new algorithms that make the interpretation of medical images more efficient and objective. We are also contributing some of the algorithms that we have previously developed. This will enable co-development on further improvements and fits our plan to make them available to the broader community.

Q&A

In what part of the patient journey will your institution most likely contribute?

We use imaging to better understand disease burden on patients, and how novel therapies may slow progression of structural damage to joints. Our focus below is on prediction, therapeutic monitoring, and precision medicine. However, we are excited to provide the algorithms we have developed to AutoPiX, so partners can explore how our algorithms may impact other parts of the patient journey.

What long-term impacts do you envision of your contribution?

Imaging used today in clinical trials requires large trials to measure disease progression. The large number of participants needed within trials places a burden on the overall patient community and extends the time it takes to get new medicines to patients.

Why is it so important?

Within AutoPiX, we hope to improve the interpretation of medical images so that trials are smaller, getting new medicines to patients faster and reducing the burden to patients.

Default team picture

Contact

Robert Janiczek
Director, Digital Measurement Strategy
Michael Deman
Director, Data Science